Drug Profile
Enhancin peptides - Micrologix Biotech
Latest Information Update: 26 Jun 2003
Price :
$50
*
At a glance
- Originator MIGENIX
- Class Antibacterials
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Bacterial infections
Most Recent Events
- 20 Jun 2001 Product in active development
- 12 Nov 1998 Preclinical development for Bacterial infections in Canada (Unknown route)